**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 17146**

**Columns: Review**

**Liver fibrosis markers of nonalcoholic steatohepatitis**

Enomoto H *et al.* Liver fibrosis markers of NASH

Hirayuki Enomoto, Yukihiro Bando, Hideji Nakamura, Shuhei Nishiguchi, Masafumi Koga

**Hirayuki Enomoto, Shuhei Nishiguchi**, Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo 663-8131, Japan

**Yukihiro Bando,** Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui 918-8236, Japan

**Hideji Nakamura,** Department of Gastroenterology and Hepatology, Nissay Hospital, Osaka 550-0012, Japan

**Masafumi Koga,** Department of Internal Medicine, Kawanishi City Hospital, Hyogo 664-8533, Japan

**Author contributions:** Enomoto h and Koga m wrote and edited the manuscript; all authors participated in the studies and were involved in the manuscript revision and approved the final version of the manuscript.

**Conflicts of interest:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Masafumi Koga, MD, PhD**, Department of Internal Medicine, Kawanishi City Hospital, Kawanishi, Hyogo 664-8533, Japan. m-koga@kawanishi-city-hospital.com

**Telephone:** +81-72-7942321

**Fax:** +81-72-7946321

**Received:** February 20, 2015

**Peer-review started:** February 22, 2015

**First decision:** April 13, 2015

**Revised:** April 27, 2015

**Accepted:** May 7, 2015

**Article in press:**

**Published online:**

**Abstract**

Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of chronic liver injury. NAFLD includes a wide range of clinical conditions from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and liver cirrhosis. The histological findings of NASH indicate hepatic steatosis and inflammation with characteristic hepatocyte injury (*e.g.*, ballooning degeneration), as is observed in the patients with alcoholic liver disease. NASH is considered to be a potentially health-threatening disease that can progress to cirrhosis. A liver biopsy remains the most reliable diagnostic method to appropriately diagnose NASH, evaluate the severity of liver fibrosis, and determine the prognosis and optimal treatment. However, this invasive technique is associated with several limitations in routine use, and a number of biomarkers have been developed in order to predict the degree of liver fibrosis. In the present article, we review the current status of noninvasive biomarkers available to estimate liver fibrosis in the patients with NASH. We also discuss our recent findings on the use of the glycated albumin-to-glycated hemoglobin ratio (the glycated albumin-to-glycated hemoglobin ratio), which is a new index that correlates to various chronic liver diseases, including NASH.

**Key words:** Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Liver fibrosis; Glycated albumin; Glycated hemoglobin

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Due to the increasing prevalence of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases. In particular, nonalcoholic steatohepatitis (NASH), a subgroup of NAFLD, has become a major health concern. A liver biopsy remains the gold standard method for the accurate diagnosis of NASH and the evaluation of the degree of liver fibrosis. However, due to the limitations associated with the performance of liver biopsies, noninvasive biomarkers have been proposed to estimate the degree of liver fibrosis. Recently, new approaches based on glycated proteins have been developed, and these methods may help to improve the management of NAFLD/NASH.

Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Hepatic steatosis indicates the accumulation of fat in excess of 5%-10% of the total liver weight[1]. Alcoholic consumption is one of the main causes of liver damage, and the presence of steatosis in alcoholic liver disease is related to the progression of liver fibrosis and cirrhosis[2,3]. Although hepatic steatosis due to nonalcoholic factors was regarded as a non-progressive benign disease, it has been noted that obese patients and those with diabetes mellitus may develop steatohepatitis that pathologically mimics alcoholic liver injury[1,4].

In 1980, Ludwig *et al*[5] reported 20 cases of nonalcoholic steatohepatitis in which the histological findings were nearly identical to alcoholic liver damage and which could progress to cirrhosis. In 1986, Schaffner *et al*[6] proposed the idea of “nonalcoholic fatty liver disease (NAFLD)” which was clinically similar to alcoholic liver disease, irrespective of the absence of an excessive alcohol intake. The definition of NAFLD requires the evidence of hepatic steatosis, either by imaging or by histology, in the absence of the typical causes for secondary hepatic fat accumulation, such as significant alcohol consumption, the use of steatogenic medication or hereditary disorders[7].

NAFLD is histologically classified into either nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH). The histological findings of NAFL demonstrate hepatic steatosis without the evidence of hepatocellular injury (*e.g.*, ballooning of the hepatocytes), and NAFL usually follows a benign clinical course. Conversely, the histological findings of NASH are barely distinguishable from those of alcoholic liver disease, which are characterized by the presence of hepatic steatosis and inflammation with a distinctive hepatocyte injury (*e.g.*, ballooning degeneration), and NASH is considered to be a potentially health-threatening disease that may progress to cirrhosis in 10-15% of patients[8]. NAFLD typically develops based on various metabolic disorders such as obesity, diabetes mellitus, and dyslipidemia; however, the prognosis and outcome of the patients with advanced liver fibrosis are predominantly determined by the liver disease-related clinical events, including hepatic failure and hepatocellular carcinoma[9,10]. Therefore, physicians are required to accurately differentiate NASH from NAFL and evaluate the severity of liver fibrosis in order to determine the prognosis and optimal treatment[7].

**ESTIMATION OF THE DEGREE OF LIVER FIBROSIS WITH NONINVASIVE BIOMARKERS**

In patients with chronic liver diseases (CLDs), continuous inflammation and tissue injury cause fibrotic changes in the liver. Liver fibrosis leads to several serious problems, including disturbed metabolic functions, an increased risk of cancer development, and portal hypertension-associated symptoms such as ascites and gastroesophageal varices.

Although imaging modalities are capable of detecting the presence of hepatic steatosis, it is not easy to diagnose NASH without a histological assessment. A liver biopsy therefore remains not only the most reliable diagnostic tool for confirming NASH, but also the most promising means of identifying many of the important clinical features of the patient, including the severity of hepatic inflammation and fibrosis[7].Although a liver biopsy can histologically determine the degree of liver fibrosis, the procedure is a costly and uncomfortable technique, which is associated with a small risk of complications[11-13]. In addition, there is the potential for a sampling error, because only 1/50000 of the organ is available for the histological assessment[12]. Furthermore, inter- and intra-investigator variances are present in up to 20% of the clinical samples[13]. Recently, several imaging tools have been developed to estimate liver fibrosis, and the clinical utility of these new modalities has been reported[1,9,14-17]. Unlike liver biopsy, these modalities can be repeatedly performed over a period of time with minimal invasion. However, these excellent but expensive items are not readily available in all institutions, while noninvasive biomarkers of fibrosis can be easily measured in a large number of patients. Therefore, there is a need for serum markers which can be routinely assessed via laboratory tests. To date, many noninvasive markers have been proposed to evaluate the degree of liver fibrosis[18-20].

During the turnover of fibrosis in the liver, the components of the extracellular matrix (ECM) are considered to be released into circulation, and some ECM-associated molecules, such as hyaluronic acid and type IV collagen, have been used as biomarkers to estimate the degree of liver fibrosis[21,22]. Additionally, a decreased platelet count was reported to correlate with the progression of liver fibrosis and therefore be a marker of the severity of liver fibrosis[23,24]. In addition to these markers, the AST-to-ALT ratio (AAR) is regarded as a well-known classical biomarker which increases with the advancement of liver fibrosis[24,25].

In 2001, Imbert-Bismut *et al*[26] investigated hepatitis C virus (HCV)-positive patients and proposed a novel index, the “FibroTest score,” which is computed based on the patient’s age, gender and levels of serum haptoglobin, α2-macroglobulin, apolipoprotein A1, γ-glutamyl transpeptidase (GGT) and bilirubin. In 2002, Forns *et al*[27] developed another scoring system, the “Forns score,” which involves an algorithm that includes the platelet count, the GGT, the patient’s age and cholesterol level. These scores are novel and important in that they allow for the degree of liver fibrosis to be assessed using only blood tests. However, the FibroTest score is a combination of six parameters, and the Forns score is calculated using a complicated formula. Therefore, neither of these markers is easy to apply in daily practice. In 2003, Wai *et al*[28] investigated several combinations of clinical variables which are commonly used in daily practice, and proposed the AST-to-platelet ratio index (APRI). This index allows for the estimation of liver fibrosis using a simple formula that is calculated using only two daily clinical variables. Subsequently, the FIB-4 index, which is determined by the age, AST, ALT, and platelet count, was proposed. In addition, many other biomarkers, such as the Fibrosis Probability Index[29,30], FibroMeter[31], Lok index[32], FibroIndex[33], Original European Liver Fibrosis (OELF) test[34] and FIBROSpect[35],were reported with regard to their clinical utility in the assessment of the degree of liver fibrosis.

**LIVER FIBROSIS MARKERS IN NAFLD/NASH**

Despite the fact that liver biopsy is the most reliable method to diagnose and evaluate the progression of NAFLD/NASH, NAFLD affects 10% to 24% of the general population in various countries[36], and it is unrealistic to perform liver biopsies in all NAFLD patients. Therefore, many biomarkers of liver fibrosis have been applied as liver fibrosis markers for NAFLD/NASH patients.

***General fibrosis markers in NAFLD/NASH***

Many biomarkers for liver fibrosis, which had been previously evaluated for the patients with viral hepatitis (particularly HCV-infected patients), have also been validated in patients with NAFLD/NASH. In addition to the patients with viral hepatitis, the serum levels of hyaluronic acid and type IV collagen were reported to increase in association with the progression of liver fibrosis in NAFLD[37,38]. Sakugawa, *et al*[38] investigated a total of 112 NAFLD patients and demonstrated these ECM-related markers to be valuable markers of liver fibrosis. Regarding the presence of fibrosis at any stage (Stage 1-4), hyaluronic acid and type IV collagen 7S were reported to have AUROCs of 0.80 and 0.83, respectively. The values of hyaluronic acid and type IV collagen 7S also had AUROCs of 0.80 and 0.82, respectively, for the prediction of advanced fibrosis (Stage 3-4). Yoneda *et al*[39] investigated a total of 1,048 patients with NAFLD and reported a significant association between the decreased platelet count and the severity of liver fibrosis. Although a platelet count was reported to show an excellent AUROC of 0.92 for the prediction of cirrhosis (Stage 4), it showed only a moderate AUROC of 0.77 for the prediction of advanced fibrosis (Stage 3-4). Irrespective of the clinical relevance of these markers, it is difficult to evaluate the degree of liver fibrosis adequately according to these variables alone.

Several liver fibrosis markers, which have been validated with multiple-variable algorithms, such as the APRI[28], FIB-4[29], FibroTest[26], and the Enhanced Liver Fibrosis (ELF) test[40], have also been validated in the NAFLD population, where they may identify patients with liver fibrosis. These indices have been reported to demonstrate AUROCs between 0.67-0.90 for the differentiation of the severity of fibrosis[41-45].

The APRI, which is a simple marker calculated by two variables (AST and platelet count), was reported to have an AUROC of 0.85 for advanced fibrosis (Stage 3-4) in 111 NAFLD patients[41]. Since the APRI is easily measurable without any special equipment, its diagnostic performance was evaluated and compared with that of the other fibrosis markers. The AUROCs of APRI for the prediction of advanced/severe fibrosis (Stage 3-4) were reported to range from 0.67 to 0.87[42]. The FIB-4 index calculated with four variables (age, AST, ALT, and platelet count) was reported to have an AUROC of 0.80 for advanced fibrosis (Stage 3-4) in 541 NAFLD patients, although the score was difficult to use for the diagnosis of NASH[43]. The FibroTest is an algorithm derived from a regression analysis of haptoglobin, α2-macroglobulin, apolipoprotein A1, bilirubin, GGT, age and gender. Its predictive values have been reported to have an AUROC of 0.81 for advanced fibrosis (Stage 3-4) and an AUROC of 0.88 for cirrhosis (Stage 4) in NAFLD[44]. The ELF test[40] has been proposed to be a modified panel of the OELF test[34]. The OELF test includes four variables [age, HA, N-terminal peptide of pro-collagen III (P3NP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP 1)], whereas the ELF test is calculated by the three variables (excluding age). When the ELF was validated for NAFLD[40], its predictive values were determined as an AUROC of 0.82 for moderate fibrosis (Stage 2-4) and an AUROC of 0.90 for advanced fibrosis (Stage 3-4). Additionally, the ELF test has been suggested to be associated with the clinical outcome[45]. However, most of these markers (other than the ELF panel) were primarily validated for the patients with HCV-related CLD, and their diagnostic performances were not adequate when these markers were applied to the patients with NAFLD/NASH. Table 1 shows the validations of general biomarkers for the histological degree of fibrosis in NAFLD/NASH patients.

***Metabolism-based fibrosis markers developed for NAFLD/NASH***

Most of the patients with NASH have several metabolic dysfunctions, including obesity, diabetes mellitus, and dyslipidemia, and their clinical features may differ from other chronic liver diseases, such as hepatitis virus-associated CLDs[7]. Therefore, simple markers derived from a logistic regression analysis of large cohorts with NAFLD/NASH have also been developed and validated. In 1999, Angulo *et al*[46] reported three factors (older age, obesity, and the presence of diabetes mellitus) to be independent predictors of severe hepatic fibrosis in the patients with NASH. In 2001, the HAIR scoring system, which was generated based on three clinical items (the presence of systemic **H**ypertension, elevated **A**LT and **I**nsulin **R**esistance) was reported to have a sensitivity of 80% and specificity of 89% for NASH in the patients undergoing bariatric surgery[47].Ratziu *et al*[48] reported the BAAT score (consisting of the **B**MI, **A**LT, **A**ge and **T**riglyceride levels) had an AUROC of 0.84 for the prediction of septal liver fibrosis (Stage 2-4). In 2007, Angulo *et al*[49] proposed the NAFLD fibrosis score (determined by the presence of diabetes, AST, ALT, the BMI, platelet count and albumin) and reported it to be a specific marker for NAFLD with an AUROC of 0.84 for advanced fibrosis (Stage 3-4). In a recent meta-analysis of 13 studies consisting of 3064 patients, the AUROC for the NAFLD fibrosis score was found to be 0.85 for the prediction of advanced fibrosis[50].The BARD score, which was determined by three items (BMI > 28 kg/m2, AST/ALT Ratio > 0.8, and **D**iabetes), was evaluated in a cohort of 827 NAFLD patients and showed an AUROC of 0.81 for predicting advanced liver fibrosis (Stage 3-4). Notably, the BARD score was reported to be valuable for excluding the patients without advanced fibrosis due to its high negative predictive value (≥ 95%)[51].

In addition to the aforementioned biomarkers, several diagnostic markers have also been proposed for the assessment of liver fibrosis in NAFLD/NASH. The FibroMeter is an index which is determined by the age, weight, fasting glucose, AST, ALT, ferritin and platelet count, and has also been validated in a NAFLD population[52]. This marker was reported to have a high diagnostic performance with an AUROC of 0.94 for significant fibrosis (Stage 2-4), 0.94 for severe fibrosis (Stage 3-4) and 0.90 for cirrhosis (Stage 4). The NAFIC score is a simple scoring system determined by three variables, including the serum ferritin level [≥ 200 ng/ml (female) or ≥ 300 ng/ml (male)], fasting insulin (≥ 10 lU/ml), and type IV collagen 7S (≥ 5.0 ng/ml). The index was reported to show an AUROC of 0.834 for significant fibrosis and 0.869 for severe fibrosis (Stage 3-4) in Japanese patients[53]. The NAFLD Diagnostic Panel is an index, which is obtained by the following items: DM, gender, BMI, triglycerides, and CK18 fragments (M30: apoptosis, M65–M30: necrosis). The panel was reported to have an AUROC of 0.80 for predicting any degree of fibrosis (Stage 1-4) and an AUROC of 0.81 for predicting advanced fibrosis (Stage 3-4)[54]. Irrespective of the excellent diagnostic performance of the methods shown in the above-described studies, the patients were heterogeneous in characteristics and were sometimes highly selected; the clinical significance of the markers should therefore be confirmed and validated in different cohorts. The biomarkers developed for NAFLD/NASH for predicting the degree of fibrosis are shown in Table 2.

**NEW APPROACHES TO LIVER FIBROSIS BY FOCUSING ON GLYCOBIOLOGY**

***Liver fibrosis markers based on glycosylated proteins***

Glycosylation is one of major posttranslational enzymatic modifications of the proteins. Because many glycosylated proteins in the serum are generated in the liver, a decreased liver function is expected to relate to the changes in protein glycosylation and recent studies suggest that serum N-glycome may be a valuable biomarker of CLDs[55-58]. According to the differences in the N-glycome patterns, two biomarkers, the GlycoCirrhoTest[55] and the GlycoFibroTest[56], have been reported to predict the presence of cirrhosis and fibrosis, respectively. In addition, new glycomics-based approaches were reported to succeed in the noninvasive evaluation of liver fibrosis[57-60], and a recently established glycosylated protein-associated maker, M2BP (Wisteria floribunda agglutinin-positive Mac-2 binding protein), was reported to be a useful marker of liver fibrosis in various CLDs, including NASH[60].

***Liver fibrosis markers based on glycated proteins: The glycated albumin-to-glycated hemoglobin ratio as a biomarker of liver fibrosis***

Although the qualitative changes of glycosylated proteins are excellent tools for estimating the degree of liver fibrosis, the methods are not readily applied to daily practice. The term “glycation” is now generally used as a non-enzymatic spontaneous modification of proteins by saccharides[61,62], and glycated proteins, particularly glycated hemoglobin (HbA1c) and glycated albumin (GA), are widely used as indices of the glycemic control in the patients with diabetes mellitus[63,64]. We herein focused on the quantitative changes of these commonly measured glycated proteins during the progression of liver fibrosis.

The lifespan of erythrocytes is approximately 120 d, and the HbA1c level typically reflects the degree of glycemia for the previous months[65]. The GA level correlates with the plasma glucose level over the previous few weeks, because the turnover of albumin is approximately three weeks[66,67]. Although the normal GA to HbA1c ratio (GA/HbA1c ratio) is approximately 3, the value changes based on the patient’s condition[68]. Because of hypersplenism, the lifespan of erythrocytes in the CLD patients is shorter than that noted in healthy individuals; thus, the HbA1c levels are lower in the patients with CLD relative to the plasma glucose level. In contrast, the turnover period of serum albumin in the CLD patients is longer than that observed in healthy persons in order to compensate for the decreased production of albumin in the liver. Therefore, the GA levels in the CLD patients are higher, relative to the degree of glycemia[68,69]. Since the HbA1c levels are lower and the GA levels are higher in the CLD patients, the GA/HbA1c ratio is considered to be higher in the patients with CLD in comparison to healthy subjects.

We previously investigated the GA/HbA1c ratio in CLD patients and reported that the GA/HbA1c ratio indicated an inverse correlation with the indicators of the hepatic function (*e.g.*, the hepaplastin test, cholinesterase and bilirubin levels), regardless of the mean plasma glucose level, thus suggesting that the GA/HbA1c ratio increases as the liver fibrosis progresses[70]. However, this report did not discuss the association of the GA/HbA1c ratio with the histological stage of fibrosis in the CLD patients. We further investigated the relationships between the GA/HbA1c ratio and the histological findings in various types of CLD, including HCV-related CLD, hepatitis B virus (HBV)-related CLD and NASH[71-73].

We studied the GA/HbA1c ratios in a total of 142 patients with HCV infection and discovered that the ratio increased with the progression of the liver fibrotic stage[71]. The GA/HbA1c ratio was additionally found to be associated with the histological severity of liver fibrosis in the patients with HBV infection and to be positively related to two well-established markers of liver fibrosis, the FIB-4 and APRI indices[72]. We further investigated the NASH patients and found that the GA/HbA1c ratio increased with an increase in the histological severity of liver fibrosis[73]. These findings suggest that the GA/HbA1c ratio is a novel biomarker of liver fibrosis in the patients with NASH as well as those infected with hepatitis viruses. The results of the GA/HbA1c ratios in the patients with various CLDs are summarized in Table 3. Although the AUROCs were not determined in these studies, comparisons of the diagnostic performance of the GA/HbA1c ratio and other biomarkers would provide important and interesting information.

Although a number of biomarkers have been developed, none of them are ideal (*i.e.*, a simple, inexpensive, reproducible, easily measurable test without any special equipment and capable of high diagnostic performance)[74]. It is notable that the rate of change of the GA/HbA1c ratio among the fibrosis stages is relatively small, and this ratio alone cannot be a decisive biomarker for the evaluation of liver fibrosis (similar to the other currently available biomarkers). In addition, some diseases and conditions are associated with high or low GA/HbA1c ratios[68]. For instance, because the GA/HbA1c ratio is affected by changes in glycemic control, it cannot to be used in patients with unstable glycemic control. The ratio may also be inaccurate as a sole liver fibrosis marker in patients with conditions that affect the level of HbA1c, such as anemia caused by non-hepatic diseases and variant hemoglobin. The ratio also differs in patients with abnormal albumin metabolism, such as nephrotic syndrome, thyroid disease and in patients who undergoing glucocorticoid therapy. Therefore, the GA/HbA1c ratio may not sufficiently reflect the degree of liver fibrosis in CLD patients with certain clinical conditions.

However, the GA/HbA1c ratio is unique and interesting in that the value can be calculated with only the levels of two common glycated proteins and correlates to the degree of liver fibrosis in various CLDs. A new biomarker based on a combination of factors, including the GA/HbA1c ratio, would provide a better noninvasive assessment of liver fibrosis. The current findings should therefore shed some new light on the evaluation of liver fibrosis.

**CONCLUSION**

NASH is one of major causes of chronic liver injury and non-viral cirrhosis. Although a liver biopsy remains the gold standard for the diagnosis of NASH and the evaluation of the severity of liver fibrosis, this technique has several disadvantages in relation to its routine and repeated use. Many serum biomarkers have been proposed in order to estimate the degree of liver fibrosis in NASH patients noninvasively. In addition, new methods based on glycated proteins have been recently developed. These new approaches may provide better insight into the clinical management of NAFLD/NASH.

**REFERENCES**

1 **Caldwell SH**, Argo CK. Non-alcoholic fatty liver disease and nutrition. In: Sherlock’s Diseases of the liver and biliary system. 12th ed. Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, editor. Oxford: Blackwell Sci Pub, 2111; 546-567

2 **Teli MR**, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. *Lancet* 1995; **346**: 987-990 [PMID: 7475591 DOI: 10.1016/S0140-6736(95)91685-7]

3 **Naveau S**, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. *Clin Gastroenterol Hepatol* 2005; **3**: 167-174 [PMID: 15704051 DOI: 10.1016/S1542-3565(04)00625-1]

4 **zelman S**. The liver in obesity. *AMA Arch Intern Med* 1952; **90**: 141-156 [PMID: 14943295]

5 **Ludwig J**, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; **55**: 434-438 [PMID: 7382552]

6 **Schaffner F**, Thaler H. Nonalcoholic fatty liver disease. *Prog Liver Dis* 1986; **8**: 283-298 [PMID: 3086934]

7 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; **55**: 2005-2023 [PMID: 22488764]

8 **Ekstedt M**, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; **44**: 865-873 [PMID: 17006923]

9 **Ratziu V**, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. *J Hepatol* 2010; **53**: 372-384 [PMID: 20494470]

10 **Nascimbeni F**, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. *J Hepatol* 2013; **59**: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]

11 **Rockey DC**, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. *Hepatology* 2009; **49**: 1017-1044 [PMID: 19243014 DOI: 10.1002/hep.22742]

12 **Bedossa P**, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003; **38**: 1449-1457 [PMID: 14647056 DOI: 10.1016/j.hep.2003.09.022]

13 **Regev A**, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 2002; **97**: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]

14 **Sandrin L**, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003; **29**: 1705-1713 [PMID: 14698338 DOI: 10.1016/j.ultrasmedbio.2003.07.001]

15 **Friedrich-Rust M**, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. *AJR Am J Roentgenol* 2007; **188**: 758-764 [PMID: 17312065 DOI: 10.2214/AJR.06.0322]

16 **Friedrich-Rust M**, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. *Radiology* 2009; **252**: 595-604 [PMID: 19703889 DOI: 10.1148/radiol.2523081928]

17 **Sporea I**, Sirli R, Popescu A, Danilă M. Acoustic Radiation Force Impulse (ARFI)--a new modality for the evaluation of liver fibrosis. *Med Ultrason* 2010; **12**: 26-31 [PMID: 21165451]

18 **Martínez SM**, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. *Hepatology* 2011; **53**: 325-335 [PMID: 21254180 DOI: 10.1002/hep.24013]

19 **Patel K**, Shackel NA. Current status of fibrosis markers. *Curr Opin Gastroenterol* 2014; **30**: 253-259 [PMID: 24671009 DOI: 10.1097/MOG.0000000000000059]

20 **Sharma S**, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. *World J Gastroenterol* 2014; **20**: 16820-16830 [PMID: 25492996]

21 **Guéchot J**, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. *J Hepatol* 1995; **22**: 103-106 [PMID: 7665843]

22 **Gabrielli GB**, Corrocher R. Hepatic fibrosis and its serum markers: a review. *Dig Dis* 1991; **9**: 303-316 [PMID: 1752069]

23 **Kajihara M**, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, Kuwana M. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. *J Gastroenterol Hepatol* 2007; **22**: 112-118 [PMID: 17201890]

24 **Fontana RJ**, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. *Hepatology* 2002; **36**: S57-S64 [PMID: 12407577]

25 **Giannini E**, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. *Dig Dis Sci* 1999; **44**: 1249-1253 [PMID: 10389705]

26 **Imbert-Bismut F**, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; **357**: 1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736(00)04258-6]

27 **Forns X**, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 2002; **36**: 986-992 [PMID: 12297848 DOI: 10.1053/jhep.2002.36128]

28 **Wai CT**, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; **38**: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]

29 **Sterling RK**, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; **43**: 1317-1325 [PMID: 16729309]

30 **Sud A**, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, Samarasinghe D, Liddle C, McCaughan GW, George J. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. *Hepatology* 2004; **39**: 1239-1247 [PMID: 15122752]

31 **Calès P**, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. *Hepatology* 2005; **42**: 1373-1381 [PMID: 16317693]

32 **Lok AS**, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. *Hepatology* 2005; **42**: 282-292 [PMID: 15986415]

33 **Koda M**, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. *Hepatology* 2007; **45**: 297-306 [PMID: 17256741]

34 **Rosenberg WM**, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology* 2004; **127**: 1704-1713 [PMID: 15578508]

35 **Patel K**, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. *J Hepatol* 2004; **41**: 935-942 [PMID: 15582126]

36 **Angulo P**. Nonalcoholic fatty liver disease. *N Engl J Med* 2002; **346**: 1221-1231 [PMID: 11961152]

37 **Suzuki A**, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. *Liver Int* 2005; **25**: 779-786 [PMID: 15998429 DOI: 10.1111/j.1478-3231.2005.01064.x]

38 **Sakugawa H**, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. *World J Gastroenterol* 2005; **11**: 255-259 [PMID: 15633226]

39 **Yoneda M**, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. *J Gastroenterol* 2011; **46**: 1300-1306 [PMID: 21750883 DOI: 10.1007/s00535-011-0436-4]

40 **Guha IN**, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* 2008; **47**: 455-460 [PMID: 18038452 DOI: 10.1002/hep.21984]

41 **Kruger FC**, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, Kotze M. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. *S Afr Med J* 2011; **101**: 477-480 [PMID: 21920102]

42 **Fitzpatrick E**, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. *World J Gastroenterol* 2014; **20**: 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851]

43 **Shah AG**, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009; **7**: 1104-1112 [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033]

44 **Ratziu V**, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol* 2006; **6**: 6 [PMID: 16503961 DOI: 10.1186/1471-230X-6-6]

45 **Parkes J**, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A, Rosenberg W. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. *Gut* 2010; **59**: 1245-1251 [PMID: 20675693 DOI: 10.1136/gut.2009.203166]

46 **Angulo P**, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; **30**: 1356-1362 [PMID: 10573511]

47 **Dixon JB**, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* 2001; **121**: 91-100 [PMID: 11438497]

48 **Ratziu V**, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. *Gastroenterology* 2000; **118**: 1117-1123 [PMID: 10833486]

49 **Angulo P**, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007; **45**: 846-854 [PMID: 17393509 DOI: 10.1002/hep.21496]

50 **Musso G**, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. *Ann Med* 2011; **43**: 617-649 [PMID: 21039302]

51 **Harrison SA**, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. *Gut* 2008; **57**: 1441-1447 [PMID: 18390575 DOI: 10.1136/gut.2007.146019]

52 **Calès P**, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J, Ducluzeaux PH, Lunel F. Comparison of blood tests for liver fibrosis specific or not to NAFLD. *J Hepatol* 2009; **50**: 165-173 [PMID: 18977552 DOI: 10.1016/j.jhep.2008.07.035]

53 **Sumida Y**, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. *J Gastroenterol* 2011; **46**: 257-268 [PMID: 20842510 DOI: 10.1007/s00535-010-0305-6]

54 **Younossi ZM**, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. *Obes Surg* 2011; **21**: 431-439 [PMID: 20532833 DOI: 10.1007/s11695-010-0204-1]

55 **Callewaert N**, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. *Nat Med* 2004; **10**: 429-434 [PMID: 15152612]

56 **Vanderschaeghe D**, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. *Mol Cell Proteomics* 2009; **8**: 986-994 [PMID: 19181623 DOI: 10.1074/mcp.M800470-MCP200]

57 **Ito K**, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. *Hepatology* 2012; **56**: 1448-1456 [PMID: 22535703 DOI: 10.1002/hep.25815.]

58 **Kuno A**, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. *Sci Rep* 2013; **3**: 1065 [PMID: 23323209 DOI: 10.1038/srep01065]

59 **Toshima T**, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, Gotoh M, Narimatsu H, Korenaga M, Mizokami M, Nishie A, Aishima S, Maehara Y. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. *J Gastroenterol* 2015; **50**: 76-84 [PMID: 24603981 DOI: 10.1007/s00535-014-0946-y]

60 **Abe M**, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. *J Gastroenterol* 2014; Epub ahead of print [PMID: 25326152]

61 **Lis H**, Sharon N. Protein glycosylation. Structural and functional aspects. *Eur J Biochem* 1993; **218**: 1-27 [PMID: 8243456]

62 **Rabbani N**, Thornalley PJ. Glycation research in amino acids: a place to call home. *Amino Acids* 2012; **42**: 1087-1096 [PMID: 20981459 DOI: 10.1007/s00726-010-0782-1]

63 **Koenig RJ**, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. *N Engl J Med* 1976; **295**: 417-420 [PMID: 934240]

64 **Bunn HF**, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. *Science* 1978; **200**: 21-27 [PMID: 635569]

65 **Tahara Y**, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. *Diabetes Care* 1995; **18**: 440-447 [PMID: 7497851]

66 **Dolhofer R**, Wieland OH. Glycosylation of serum albumin: elevated glycosyl-albumin in diabetic patients. *FEBS Lett* 1979; **103**: 282-286 [PMID: 467671]

67 **Guthrow CE**, Morris MA, Day JF, Thorpe SR, Baynes JW. Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. *Proc Natl Acad Sci USA* 1979; **76**: 4258-4261 [PMID: 291961]

68 **Koga M**. Glycated albumin; clinical usefulness. *Clin Chim Acta* 2014; **433**: 96-104 [PMID: 24631132 DOI: 10.1016/j.cca.2014.03.001]

69 **Koga M**, Kasayama S, Kanehara H, Bando Y. CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. *Diabetes Res Clin Pract* 2008; **81**: 258-262 [PMID: 18513821 DOI: 10.1016/j.diabres.2008.04.012]

70 **Bando Y**, Kanehara H, Toya D, Tanaka N, Kasayama S, Koga M. Association of serum glycated albumin to haemoglobin A1C ratio with hepatic function tests in patients with chronic liver disease. *Ann Clin Biochem* 2009; **46**: 368-372 [PMID: 19675058 DOI: 10.1258/acb.2009.008231]

71 **Aizawa N**, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. *World J Hepatol* 2012; **4**: 11-17 [PMID: 22312451 DOI: 10.4254/wjh.v4.i1.11]

72 **Enomoto H**, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K, Hashimoto K, Ishii A, Takashima T, Iwata K, Saito M, Imanishi H, Iijima H, Nishiguchi S. An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. *Gastroenterol Res Pract* 2014; **2014**: 351396 [PMID: 24693282 DOI: 10.1155/2014/351396]

73 **Bando Y**, Kanehara H, Aoki K, Toya D, Notsumata K, Tanaka N, Enomoto H, Nishiguchi SH, Nakasho K, Nakamura H, Kasayama S, Koga M. The glycated albumin to glycated haemoglobin ratio increases along with the fibrosis stage in non-alcoholic steatohepatitis. *Ann Clin Biochem* 2012; **49**: 387-390 [PMID: 22715293 DOI: 10.1258/acb.2012.011139]

74 **Pearce SG**, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. *Biomark Res* 2013; **1**: 7 [PMID: 24252302 DOI: 10.1186/2050-7771-1-7]

**P-Reviewer:** Carulli l, Daltro c, de Oliveira CPMS, Federico A, Gong ZJ, Kayadibi H, Sato K **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 General liver fibrosis markers for nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Biomarkers** | **Items** | **Cohort** | **AUROC for diagnosis** | **Ref.** |
| General markers for liver fibrosis  (solo makers) |  |  |  |  |
| Hyaluronic acid |  | 112 | Stage 1-4: 0.80, Stage3-4: 0.80 | Sakugawa, *et al*[38], 2005 |
| Type IV collagen 7S |  | 112 | Stage 1-4: 0.83, Stage3-4: 0.82 | Sakugawa, *et al*[38], 2005 |
| Platelet count |  | 1048 | Stage 3-4: 0.77, Stage4: 0.92 | Yoneda *et al*[39], 2011 |
| General markers for liver fibrosis  (algorithm based makers) |  |  |  |  |
| FibroTest | α2-macroglobulin, Apolipoprotein A1, Haptoglobin, GGT, Bilirubin | 267 | Stage 2-4: 0.81, Stage 4: 0.88 | Ratziu *et al*[44], 2006 |
| APRI | AST, Platelet count | 111 | Stage 3-4: 0.85 | Kruger *et al*[41], 2011 |
| FIB4 index | Age, AST, ALT, Platelet count | 541 | Stage 3-4: 0.802 | Shah *et al*[43], 2009 |
| ELF (Enhanced liver fibrosis panel) | HA, TIMP1, P3NP | 192 | Stage 2-4: 0.82, Stage 3-4: 0.9 | Guha *et al*[40], 2008 |

APRI: AST-to-platelet ratio index.

**Table 2 Liver fibrosis markers developed for nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Liver fibrosis markers for NAFLD | Items | Cohort | AUROC for diagnosis | Ref. |
| HAIR | Hypertension, ALT, Insulin Resistance | 105 | Stage 3-4: 0.90 | Dixon *et al*[47], 2001 |
| BAAT score | BMI, Age, ALT, Triglycerides | 93 | Stage 2-4: 0.84 | Ratziu *et al*[48], 2000 |
| NAFLD Fibrosis score | Age, BMI, Hyperglycemia, Platelet count, Albumin, AST/ALT ratio | 733 | Stage 3-4: 0.84 | Angulo *et al*[49], 2007 |
| BAAD score | BMI, AST/ALT ratio, DM | 827 | Stage 3-4: 0.81 | Harrison *et al*[51], 2008 |
| FibroMeter NAFLD | Glucose, AST, Platelet count, ALT, Ferritin, Body Weight, Age | 235 | Stage 2-4: 0.943 | Calès *et al*[52], 2009 |
| NAFLD Diagnostic Panel | DM, Gender, BMI, Triglycerides,  CK18 fragments (apoptotic and necrotic) | 79 | 1Stage 1-4: 0.81,2Stage 2-4: 0.80 | Younossi *et al*[54], 2011 |
| NAFIC score | Ferritin, IRI, type IV collagen 7S | 619 | Stage 2-4: 0.834, Stage 3-4: 0.869 | Sumida *et al*[53], 2011 |

1Presence of any degree of fibrosis; 2Presence of advanced fibrosis (at least moderate portal or pericellular fibrosis, bridging fibrosis, or cirrhosis). NAFLD: nonalcoholic fatty liver disease.

**Table 3 glycated albumin-to-glycated hemoglobin ratio (GA/HbA1c ratio) and liver fibrosis**

|  |  |  |  |
| --- | --- | --- | --- |
| Patients | Cohort | Main results | Ref. |
| Various CLDs | 82 | The GA/HbA1c ratio was associated with hepatic functions (decreasing hepaplastin test and cholinesterase levels) independent of the mean plasma glucose levels. | Bando *et al*[70], 2009 |
| HCV-positive CLD | 142 | The GA/HbA1c ratio increased in association with the histological severity of liver fibrosis. The diagnostic performance of APRI improved when combined with the GA/HbA1c ratio. | Aizawa *et al*[72], 2012 |
| HBV-positive CLD | 176 | The GA/HbA1c ratio increased in line with the severity of fibrosis. The GA/HbA1c ratios were inversely correlated with four variables of liver function (the prothrombin time percentage, platelet count, albumin value and cholinesterase value). | Enomoto *et al*[73], 2014 |
| NASH | 36 | The GA/HbA1c ratio was negatively correlated with ALT and platelet count. The GA/HbA1c ratio was positively correlated with the degree of liver fibrosis. | Bando *et al*[74], 2012 |

CLDs: chronic liver diseases; HCV: hepatitis C virus; HBV: Hepatitis B virus; NASH: nonalcoholic steatohepatitis.